Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

JAK inhibitors have top risk for herpes zoster among newer RA DMARDs

Key clinical point: Herpes zoster risk is increased with rheumatoid arthritis (RA) treatment, supporting the need for vaccination.

Major finding: Janus kinase (JAK) inhibitor treatment was associated with a fivefold (HR, 5.0; P < .0001) higher risk of herpes zoster, compared with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).

Study details: Analysis of 12,470 patients enrolled in the German biologics register RABBIT from 2007 onwards and who had been treated with various biologic and targeted synthetic DMARDs.

Disclosures: RABBIT is supported by a joint unconditional grant from AbbVie, Amgen, Bristol-Myers Squibb, Celltrion, Hexal, Lilly, Merck Sharp & Dohme, Mylan, Pfizer, Roche, Samsung Bioepis, Sanofi-Aventis, and UCB. Dr. Strangfeld has received speakers fees from AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche, Sanofi-Aventis, and UCB.

Citation:

Strangfeld A et al. Ann Rheum Dis. 2020;79[suppl 1]:150. Abstract OP0238